Medicovestor, Inc.

🚀 Big News for Medicovestor! We are thrilled to announce the issuance/approval of 3 patents by the USPTO! This achievement marks a significant milestone in our journey, reinforcing our commitment to innovation in healthcare investment and advancing next-gen medical solutions. This patent approval isn’t just a win for us – it’s a step forward in transforming how we identify and support revolutionary medical breakthroughs. Stay tuned as we continue pushing boundaries! #ADC #Medicovestor #oncology #ovariancancer #metastatic #ADoBind #ADoTope

Seah Lim MD PhD, CEO, and Benjamin Vali MS RA, Chief Regulatory and Strategy Officer at Medicovestor, Inc. wish to thank Sophia Meng and Wusong Lue for hosting our visit to Porton Pharma Solutions Ltd. in Shanghai. #ADC #ADoBind #ADoTope #solidtumors #Pancreaticcancer #Ovariancancer #Hope

Congratulations to Seah Lim, our CEO, who has been invited to speak at Navigating Antibody & ADC Advancements: Expert Perspectives and Industry Tr! Make sure to attend it on September 24. #ADC #ovariancancer #ADoBind #ADoTope #hope https://lnkd.in/eUQG9t8P

We congratulate Seah Lim, our CEO, for being selected as one of eight finalists to showcase Medicovestor, Inc.'s first-in-class #antibodydrugconjugate platforms at BioSpark Group CvilleBioHub meeting in Charlotteville, VA on September 26, 2024. He will share the unique features of our #antibodydrugconjugate platforms that focus on the 'A' of #ADC, rather than 'DC' of #ADC. #ADC #ADoBind #ADoTope #ovariancancer #hope

Seah Lim, our CEO, and Ken Tang, our CFO, at the inaugural JP Morgan Asset Management: Life Sciences Innovation Summit in Abu Dhabi. Seah Lim will present our first-in-class #ADC program tomorrow. Good luck! #ADC #Ovariancancer #cervicalcancer #hope #solidtumors #Innovations

We would like to congratulate Zhi Xin Phuna and Seah Lim, our CEO, at Medicovestor, Inc. for the publication of this Review manuscript describing some of the approaches we are taking in developing our #ADC. https://lnkd.in/eT5y3FGn #ADC #Solidtumors #ADoBind #ovariancancer #cervicalcancer #hope

Our Chief Business Officer,Lin Hu Ong presented our first-in-class ADC at the Asia Biopartnering 2024 event in Singapore. #ADC #medicovestor #asiabiopartnering

Our Chief Business Officer, Lin Hu Ong is at the Asia Biopartnering in Singapore today and tomorrow, presenting our groundbreaking first-in-class ADC and exploring investment opportunities.

Medicovestor, Inc. is honored to welcome Robert Niecestro PhD to its board. Robert brings to the company his extensive experience and expertise in drug development, including #biologics. He will join Farrah Ofner and Dr. William Clementi PhD to guide the company forward in its development of innovative therapies. Robert is the Managing Director of AccelaPHARM, LLC and served as a strategic regulatory consultant to Axsome Therapeutics, Inc., BeyondSpring, BioVie Inc., Checkpoint Therapeutics Inc, Citius Pharmaceuticals, Inc., Cyprium Therapeutics, Inc, ES Therapeutics, Fortress Biotech, Hillstream Pharma Inc., and TG Therapeutics, Inc. Robert’s role at these companies was to develop comprehensive development plans from #IND filings to #NDA submissions. From 2012 until September 2018, Robert served as consultant for the development of AXS-02 and AXS-05 from Axsome Therapeutics, Inc.. Robert was involved in the in-licensing and regulatory development of CK-101 from Checkpoint Therapeutics Inc. At ES Therapeutics, Robert was responsible for managing the development of ES-481. Robert was responsible for the in-licensing of IV tramadol into Fortress Biotech for Avenue Therapeutics. Robert was a co-founder of Cyprium Therapeutics, Inc and assisted in the in-licensing and #CRADA with the #NIH for Copper Hisitidinate for Menkes Disease. Robert served as the Executive Vice President of Clinical and Regulatory Affairs for TG Therapeutics, Inc. from 2012 to February 2018 and consulted with TG Therapeutics, Inc. on the filing and approval of an #NDA for their #anti-CD20 monoclonal antibody for the treatment of #multiplesclerosis. Robert served as the Vice President of Regulatory Affairs for Keryx Pharmaceuticals Pvt Ltd from 2004 to 2012 and led the development team for ferric citrate and was a regulatory consultant to Stemline Therapeutics prior to their #IPO. Prior to 2004, Robert held numerous senior management positions in the pharmaceutical industry serving as the Vice President of Clinical Development for ANDRX LABORATORIES INC; Senior Director, Clinical Development and Therapeutic Head for Gastrointestinal, Oncology and Stroke at Eisai US; and Director, Clinical Operations and #NDA Planning for Organon Inc. Robert has been involved in the filing of over 60 #INDs; approval of 14 New Drug Applications (#NDAs) or Biologic Licensing Agreements (#BLAs) with 1 #NDA actively undergoing review with the #FDA; has over 75 peer-reviewed scientific presentations, abstracts and/or publications, and holds 4 patents. #ADC #ADoBind #solidtumors #ovariancancer #cervicalcancer #hope

Excited to be sharing our first-in-class ADC!